Keytruda plus Padcev for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—Keytruda (immunotherapy) and Padcev (a targeted drug that delivers chemotherapy to cancer cells)—for people with advanced melanoma that has stopped responding to standard immunotherapy. The goal is to see if this new pair can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have advanced melanoma that cannot be removed by surgery or has spread to other parts of the body.
- You have already tried an immunotherapy drug (like Keytruda or Opdivo) and the cancer got worse while on it or within 12 weeks of your last dose.
- If your melanoma has a BRAF mutation, you must have also tried a targeted therapy (BRAF/MEK inhibitors) before joining.
- You have at least one measurable tumor (by scan) and are in generally good health (ECOG 0 or 1, meaning you can do daily activities).
- You have not had enfortumab vedotin (Padcev) or similar drugs before, and you do not have poorly controlled diabetes, active brain metastases needing steroids, or a current serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.